TY - JOUR
T1 - American Founder Mutation for Lynch syndrome
T2 - Prevalence estimates and implications
AU - Lynch, Henry T.
AU - De La Chapelle, Albert
AU - Hampel, Heather
AU - Wagner, Anja
AU - Fodde, Riccardo
AU - Lynch, Jane F.
AU - Okimoto, Ross
AU - Clark, Mary Beth
AU - Coronel, Stephanie
AU - Trowonou, Abdon
AU - Fu, Yun Xin
AU - Haynatzki, Gleb R.
AU - Gong, Gordon
PY - 2006/1/15
Y1 - 2006/1/15
N2 - BACKGROUND. Recently, a new founder mutation, an exon 1-6 deletion in a mismatch repair gene (MMR), MSH2, in nine kindreds with Lynch syndrome was reported. In 3 of the kindreds this mutation was traced by genealogy through 11-12 generations to a common founder, and thus termed the American Founder Mutation (AFM). Since then, 13 additional 'unrelated' kindreds with AFM were detected by a recently designed single polymerase chain reaction. This test might serve as first-line screening for Lynch syndrome mutations, provided AFM was prevalent, which is assessed in the current study. METHODS. The number of current AFM carriers and the incidence of Lynch syndrome caused by AFM were estimated based on population growth of mutation carriers derived from genealogy data. For cross-checking, its annual incidence was also estimated based on published epidemiology data. RESULTS. There are 18,981 (5th and 95th percentiles, 6038 and 34,466, respectively) expected current AFM carriers, or 160 (range 51-290) Lynch syndrome cases diagnosed per year due to AFM estimated based on genealogy data. The incidence estimate closely overlaps with that based on published epidemiology data, which is 114-400 cases per year. COMCLUSIONS. A large number of AFM carriers are likely to exist in the U.S., which harbors significant implications for cancer control. Given the ease of detection, testing for AFM not only among members of the existing AFM families, but also among all patients with Lynch syndrome in the U.S. is proposed.
AB - BACKGROUND. Recently, a new founder mutation, an exon 1-6 deletion in a mismatch repair gene (MMR), MSH2, in nine kindreds with Lynch syndrome was reported. In 3 of the kindreds this mutation was traced by genealogy through 11-12 generations to a common founder, and thus termed the American Founder Mutation (AFM). Since then, 13 additional 'unrelated' kindreds with AFM were detected by a recently designed single polymerase chain reaction. This test might serve as first-line screening for Lynch syndrome mutations, provided AFM was prevalent, which is assessed in the current study. METHODS. The number of current AFM carriers and the incidence of Lynch syndrome caused by AFM were estimated based on population growth of mutation carriers derived from genealogy data. For cross-checking, its annual incidence was also estimated based on published epidemiology data. RESULTS. There are 18,981 (5th and 95th percentiles, 6038 and 34,466, respectively) expected current AFM carriers, or 160 (range 51-290) Lynch syndrome cases diagnosed per year due to AFM estimated based on genealogy data. The incidence estimate closely overlaps with that based on published epidemiology data, which is 114-400 cases per year. COMCLUSIONS. A large number of AFM carriers are likely to exist in the U.S., which harbors significant implications for cancer control. Given the ease of detection, testing for AFM not only among members of the existing AFM families, but also among all patients with Lynch syndrome in the U.S. is proposed.
KW - Carrier
KW - Colorectal carcinoma
KW - Founder mutation
KW - Lynch syndrome
UR - http://www.scopus.com/inward/record.url?scp=30744433609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30744433609&partnerID=8YFLogxK
U2 - 10.1002/cncr.21624
DO - 10.1002/cncr.21624
M3 - Article
C2 - 16353207
AN - SCOPUS:30744433609
SN - 0008-543X
VL - 106
SP - 448
EP - 452
JO - Cancer
JF - Cancer
IS - 2
ER -